Patrick J O'Hara

US Patent:

20020137159, Sep 26, 2002

Filed:

Aug 22, 2001

Appl. No.:

09/934814

Inventors:

Si Lok - Seattle WA, US
James Holloway - Seattle WA, US
Patrick O'Hara - Seattle WA, US

International Classification:

C12N009/00
C07H021/04
C12P021/02
C12N005/06

US Classification:

435/183000, 435/069100, 435/325000, 435/320100, 536/023200

Abstract:

Human phermones may be used to alleviate anxiety, promote beneficial moods, and to alter hypothalamic functions, such as satiety, energy balance, and reproductive biology. The present invention provides a new group of human pheromone polypeptides, collectively designated “ZHMUP-1.”

US Patent:

20030100046, May 29, 2003

Filed:

Mar 12, 1997

Appl. No.:

08/815773

Inventors:

JAMES W. BAUMGARTNER - SEATTLE WA, US
THERESA M. FARRAH - SEATTLE WA, US
DONALD C. FOSTER - SEATTLE WA, US
FRANK J. GRANT - SEATTLE WA, US
PATRICK J. O'HARA - SEATTLE WA, US

International Classification:

C07K014/72
C12P021/02
C12N005/06
C07H021/04

US Classification:

435/069100, 536/023500, 530/350000, 435/320100, 435/325000

Abstract:

Novel receptor polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. The polypeptides comprise an extracellular domain of a cell-surface receptor that is expressed in testis cells. The polypeptides may be used within methods for detecting ligands that promote the proliferation and/or differentiation of testis cells, and may also be used in the development of male-specific contraceptives and infertility treatments.

US Patent:

20030166070, Sep 4, 2003

Filed:

May 9, 2002

Appl. No.:

10/142465

Inventors:

Si Lok - Seattle WA, US
James Holloway - Seattle WA, US
Patrick O'Hara - Seattle WA, US

International Classification:

C12P021/02
C12N005/06
C07K014/435
C07H021/04

US Classification:

435/069100, 435/320100, 435/325000, 530/399000, 536/023200

Abstract:

Human phermones may be used to alleviate anxiety, promote beneficial moods, and to alter hypothalamic functions, such as satiety, energy balance, and reproductive biology. The present invention provides a new group of human pheromone polypeptides, collectively designated “ZHMUP-1.”

US Patent:

20050020824, Jan 27, 2005

Filed:

Jul 12, 2004

Appl. No.:

10/887863

Inventors:

James Baumgartner - Thousands Oaks CA, US
Theresa Farrah - Cairo, EG
Donald Foster - Lake Forest Park WA, US
Frank Grant - Seattle WA, US
Patrick O'Hara - Seattle WA, US

International Classification:

C07H021/04
C07K014/705

US Classification:

536023500, 530350000, 435069100, 435320100, 435325000

Abstract:

Novel receptor polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. The polypeptides comprise an extracellular domain of a cell-surface receptor that is expressed in testis cells. The polypeptides may be used within methods for detecting ligands that promote the proliferation and/or differentiation of testis cells, and may also be used in the development of male-specific contraceptives and infertility treatments.

US Patent:

52003400, Apr 6, 1993

Filed:

May 22, 1987

Appl. No.:

7/053412

Inventors:

Donald C. Foster - Seattle WA
Eileen R. Mulvihill - Seattle WA
Patrick J. O'Hara - Seattle WA
Kurt Pingel - Farum, DK
Shinji Yoshitake - Ibaraki, JP

Assignee:

ZymoGenetics, Inc. - Seattle WA

International Classification:

C12N 961
C12N 1500
C12N 1558
C12N 1535

US Classification:

424 9464

Abstract:

Zymogens of proteins having fibrinolytic activity are disclosed. The proteins are cleavable by thrombin, the cleavage resulting in the stimulation of fibrinolytic activity. Suitable proteins which may be modified in accordance with the present invention include tissue plasminogen activator, urokinase, and plasminogen variants. The modified molecules are substantially clot-specific, in view of the large amounts of thrombin associated with clots in vivo.

US Patent:

59196351, Jul 6, 1999

Filed:

May 30, 1995

Appl. No.:

8/452930

Inventors:

Wayne R. Kindsvogel - Seattle WA
Laura J. Jelinek - Seattle WA
Paul O. Sheppard - Redmond WA
Francis J. Grant - Seattle WA
Joseph L. Kuijper - Bothell WA
Donald C. Foster - Seattle WA
Si Lok - Seattle WA
Patrick J. O'Hara - Seattle WA

Assignee:

ZymoGenetics, Inc. - Seattle WA

International Classification:

G01N 33566
C12N 1512
C12N 510
C07K 14705

US Classification:

435 72

Abstract:

The present invention provides isolated DNA molecules comprising a DNA segment encoding a glucagon receptor. Also provided are DNA constructs comprising a first DNA segment encoding a glucagon receptor operably linked to additional DNA segments required for the expression of the first DNA segment, as well as host cells containing such DNA constructs. The present invention also provides a method for detecting the presence of glucagon antagonists, comprising the steps of (a) exposing a compound in the presence of a glucagon against to a recombinant glucagon receptor coupled to a response pathway under conditions and for time sufficient to allow binding of the compound to the receptor and an associated response through the pathway, and (b) detecting a reduction in the stimulation of the response pathway resulting from the binding of the compound to the glucagon receptor, relative to the stimulation of the response pathway by the glucagon agonist alone and therefrom determining the presence of a glucagon antagonist.

US Patent:

57767254, Jul 7, 1998

Filed:

Jul 1, 1993

Appl. No.:

8/086631

Inventors:

Wayne R. Kindsvogel - Seattle WA
Laura J. Jelinek - Seattle WA
Paul O. Sheppard - Redmond WA
Francis J. Grant - Seattle WA
Joseph L. Kuijper - Bothell WA
Donald C. Foster - Seattle WA
Si Lok - Seattle WA
Patrick J. O'Hara - Seattle WA

Assignee:

ZymoGenetics, Inc. - Seattle WA

International Classification:

C12N 1512
C07K 1472

US Classification:

435 691

Abstract:

The present invention provides isolated DNA molecules comprising a DNA segment encoding a glucagon receptor. Also provided are DNA constructs comprising a first DNA segment encoding a glucagon receptor operably linked to additional DNA segments required for the expression of the first DNA segment, as well as host cells containing such DNA constructs. The present invention also provides a method for detecting the presence of glucagon antagonists, comprising the steps of (a) exposing a compound in the presence of a glucagon against to a recombinant glucagon receptor coupled to a response pathway under conditions and for time sufficient to allow binding of the compound to the receptor and an associated response through the pathway, and (b) detecting a reduction in the stimulation of the response pathway resulting from the binding of the compound to the glucagon receptor, relative to the stimulation of the response pathway by the glucagon agonist alone and therefrom determining the presence of a glucagon antagonist.

US Patent:

52815200, Jan 25, 1994

Filed:

Sep 12, 1990

Appl. No.:

7/581342

Inventors:

Patrick J. O'Hara - Seattle WA
Frederick S. Hagen - Seattle WA
Francis J. Grant - Seattle WA
Robert S. Munford - Dallas TX

Assignee:

ZymoGenetics, Inc. - Seattle WA
Board of Regents University of Texas System - Austin TX

International Classification:

C12N 1500
C12N 1556
C12N 1580
C12N 1585

US Classification:

435 691

Abstract:

Methods are disclosed for producing acyloxyacyl hydrolase. The protein is produced from eukaryotic host cells transformed or transfected with DNA construct(s) containing information necessary to direct the expression of acyloxyacyl hydrolase. The DNA constructs generally include the following operably linked elements: a transcriptional promoter; DNA sequence encoding acyloxyacyl hydrolase, the small subunit of acyloxyacyl hydrolase or the large subunit of acyloxyacyl hydrolase; and a transcriptional terminator. In addition, isolated DNA sequences encoding acyloxyacyl hydrolase and isolated DNA sequences encoding the small or large subunit of acyloxyacyl hydrolase are disclosed.